12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Elagolix: Phase IIb started

Neurocrine began a double-blind, placebo-controlled Phase IIb trial to evaluate elagolix alone and in combination with estradiol/norethindrone acetate therapy for 6 months in about 280 female patients ages 18-49 years with...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >